Adipsin Modulation for Pancreatic Beta Cell Function Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular link between obesity, adipose inflammation, and pancreatic beta cell malfunction in type 2 diabetes remains unclear, necessitating the identification of molecular regulators for diagnostic, prognostic, and therapeutic agents to effectively control pancreatic beta cell disorders.
Innovation Solution
Adipsin, an adipokine, is discovered to improve pancreatic beta cell function by promoting glucose-dependent insulin secretion, with methods involving the administration of nucleic acids or biologically active fragments encoding adipsin or adipsin polypeptides to enhance insulin secretion, glucose tolerance, and pancreatic beta cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adipsin is administered to improve pancreatic beta cell function, then insulin secretion and glucose tolerance are improved, but the mechanism linking obesity, adipose inflammation, and beta cell malfunction remains unclear
Solution Approach 1:
Adipsin serves as an intermediary molecule that connects adipose tissue function to pancreatic beta cell physiology. The patent identifies adipsin as the mediating agent that, when administered, improves beta cell function and insulin secretion, thereby establishing a molecular link between adipose tissue and pancreatic function in the context of obesity and type 2 diabetes
2Reliability
If adipsin agents are used to increase insulin secretion, then glucose tolerance improves, but there is a risk of causing hypoglycemia
Solution Approach 1:
The patent utilizes parameter changes by administering varying doses of adipsin (e.g., 1 μg/kg, 10 μg/kg, 100 μg/kg body weight) to achieve optimal glucose tolerance improvement while avoiding hypoglycemia. The dosage regimen is carefully controlled to maintain blood glucose within normal ranges, demonstrating parameter optimization to balance therapeutic benefit against potential adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of adipsin agents increases insulin secretion, improves glucose tolerance, and enhances pancreatic beta cell function, effectively reducing elevated glucose levels without causing hypoglycemia and maintaining normal glucose levels for an extended period.
Implementation Method 1
Adipsin, an adipokine, is discovered to improve pancreatic beta cell function by promoting glucose-dependent insulin secretion
Implementation Method 2
methods involving the administration of nucleic acids or biologically active fragments encoding adipsin or adipsin polypeptides to enhance insulin secretion, glucose tolerance, and pancreatic beta cell proliferation
Data Source
AI summary
The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression.